It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Hepatocellular Carcinoma Treatment Study

Clinical Trial Title: 
A study evaluating the overall survival rate of subjects with hepatocellular carcinoma (HCC) treated with TheraSphere and/or standard-of-care (SOC) sorafenib.
Clinical Trial Protocol ID: 
12102501
Clinical Trial Investigator Name: 
Sheila Eswaran, MD
Clinical Trial Protocol Description: 

This research study investigates the overall survival rate in patients diagnosed with unresectable hepatocellular carcinoma (HCC) using TheraSphere treatment with SOC sorafenib therapy vs SOC sorafenib alone. Overall, 600 patients will be recruited for this study. Rush University Medical Center expects to enroll 3 patients. The treatment will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have unresectable HCC.
  • Be eligible to receive standard-of-care sorafenib.

You will be excluded from the study if any of the following criteria apply to you:

  • Have main portal vein thrombosis (PVT).
  • Have had a liver transplant.
  • Have already been treated with TACE, yttrium-90 or sorafenib within 2 months of randomization).

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Liver, Biliary and Pancreatic Disorders
Contact Phone: 
(312) 942-1372
Contact Name: 
Lelani Fetrow